Our results show the existence of an important new isoform of Tau and suggest that further research on this less aggregation-prone Tau may help to develop future therapies for Alzheimer’s disease and other tauopathies. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.